Formestane aromatase inhibitors  

CGP 32349 - CGP 32 349 - CGP-32349 - Lentaron - 4-OHA - 4-hydroxyandrostenedione - formestane      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultclinical benefit objective response (ORR)

advanced breast cancer (metastatic)  

Kleeberg, 1997   formestaneanastrozolenegative17%-44%
Thuerlimann, 1997   formestanemegestrol acetatenegative-13%-1%
Freue, 2000   formestanemegestrol acetatesuggesting24%
Perez Carrion, 1994   formestanetamoxifennegative10%12%